Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DermaPro
- Development stage
- Phase 3
- Lead developer
- DermaTools Biotech
- Administration
- Topical, Oral
01
Overview
DermaPro is an active substance developed by DermaTools Biotech, a subsidiary of CytoTools (now BioXXmed), for the treatment of wound healing indications. It is currently undergoing clinical development for ulcus cruris in Europe and is being prepared for clinical trials in the USA for the same indication. Additionally, it has undergone Phase II/III trials for diabetic foot ulcers in India through a partnership with Centaur Pharmaceuticals.
- Brand names
- DermaPro
Beyond the preview
Go deeper on DermaPro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DermaPro.